Display options
Cite
Binti Yusof NS, Ameli F, Sabrina Florence Ch, et al. Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues. Asian Pac J Cancer Prev. 2017;18(4):1045-1050doi: 10.22034/APJCP.2017.18.4.1045.
Binti Yusof, N. S., Ameli, F., Sabrina Florence, C. h., Mustangin, M., Abd Rahman, F., & Masir, N. (2017). Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues. Asian Pacific journal of cancer prevention : APJCP, 18(4), 1045-1050. https://doi.org/10.22034/APJCP.2017.18.4.1045
Binti Yusof, Nor Syahida, et al. "Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues." Asian Pacific journal of cancer prevention : APJCP vol. 18,4 (2017): 1045-1050. doi: https://doi.org/10.22034/APJCP.2017.18.4.1045
Binti Yusof NS, Ameli F, Sabrina Florence Ch, Mustangin M, Abd Rahman F, Masir N. Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues. Asian Pac J Cancer Prev. 2017 Apr 01;18(4):1045-1050. doi: 10.22034/APJCP.2017.18.4.1045. PMID: 28547939; PMCID: PMC5494214.
Copy Download .nbib Format: NLM
Share it on

Asian Pac J Cancer Prev. 2017 Apr 01;18(4):1045-1050. doi: 10.22034/APJCP.2017.18.4.1045.

Expression of the Class II and III Beta-Tubulin in Neoplastic and Non-Neoplastic Lymphoid Tissues.

Asian Pacific journal of cancer prevention : APJCP

Nor Syahida Binti Yusof, Fereshteh Ameli, Chandramaya Sabrina Florence, Muaatamarulain Mustangin, Faridah Abd Rahman, Noraidah Masir

Affiliations

  1. Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. Email: [email protected]

PMID: 28547939 PMCID: PMC5494214 DOI: 10.22034/APJCP.2017.18.4.1045

Abstract

Aim: Abnormal expression patterns of beta-tubulin isotypes may provide a molecular rationale for the behaviour of lymphoma subtypes. In the present study class II and III beta-tubulin expression was assessed in non-neoplastic and neoplastic lymphoid tissues with reference to potential utility as new tumour biomarkers. Methods and results: In this cross-sectional study class II and III beta-tubulin expression was assessed in 304 neoplastic and 20 normal lymphoid tissues using qualitative and semi-quantitative immunohistochemistry. Class II beta-tubulin was found to be positive in the germinal centres, mantle zone and interfollicular regions of normal lymphoid tissues. It was also expressed in 15/15 (100%) lymphoblastic lymphomas, 229/231 (99%) mature B cell lymphomas, 22/22 (100%) T/NK-cell lymphomas and 36/36(100%) classical Hodgkin lymphomas. Class III beta-tubulin in contrast was germinal centre restricted and more selective, being found mainly in classical Hodgkin lymphomas (34/36 (94%)). It was also expressed in 58/171(34%) DLBCL, 11/12 (92%) mantle cell lymphomas and 6/6 (100%) Burkitt lymphomas. Other mature B cell, T/NK cell lymphomas and precursor lymphoblastic lymphomas were usually negative. Conclusions: Class II beta-tubulin shows ubiquitous expression in neoplastic and non-neoplastic lymphoisd tissues. In contrast, Class III beta-tubulin is germinal centre-restricted. Its consistent expression in classical Hodgkin lymphomas may point to use in the identification of Reed-Sternberg and Hodgkin cells. Its expression in a proportion of DLBCL, Burkitt and mantle cell lymphomas is of interest as this may be related to their aggressiveness.

Creative Commons Attribution License

Keywords: lymphoid lesion; lymphoma; immunohistochemistry

References

  1. J Biol Chem. 2003 Nov 14;278(46):45082-93 - PubMed
  2. Mol Cancer Ther. 2004 Sep;3(9):1137-46 - PubMed
  3. Clin Exp Metastasis. 2014 Jan;31(1):101-10 - PubMed
  4. Am J Surg Pathol. 2010 May;34(5):645-55 - PubMed
  5. Blood. 2003 Oct 15;102(8):2868-76 - PubMed
  6. Leukemia. 2012 Sep;26(9):1899-907 - PubMed
  7. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  8. Front Oncol. 2014 Jun 18;4:153 - PubMed
  9. Ann Oncol. 2000;11 Suppl 1:3-10 - PubMed
  10. Cancer Res. 2008 Dec 1;68(23):9817-24 - PubMed
  11. Cell Motil Cytoskeleton. 2008 Aug;65(8):675-85 - PubMed
  12. Pathologica. 2010 Jun;102(3):83-7 - PubMed
  13. Histopathology. 2011 Jan;58(1):4-14 - PubMed
  14. Mol Cancer Ther. 2005 Dec;4(12):2001-7 - PubMed
  15. Pathol Int. 2012 Apr;62(4):287-90 - PubMed
  16. Cancer. 2013 Jul 15;119(14):2582-92 - PubMed
  17. Nat Rev Drug Discov. 2010 Oct;9(10):790-803 - PubMed
  18. Blood. 2011 May 12;117(19):5019-32 - PubMed
  19. PLoS One. 2011;6(6):e21717 - PubMed
  20. Int J Clin Exp Pathol. 2010 Oct 11;3(8):815-21 - PubMed
  21. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed
  22. Cytoskeleton (Hoboken). 2011 Jun;68(6):355-62 - PubMed
  23. Cancer Res. 2007 Nov 15;67(22):10703-10 - PubMed

Publication Types